Investigating a device for treating restless legs syndrome

Form, Fit and Function Feasibility Study

This study is testing a new device to see if it can help people with restless legs syndrome feel better and sleep more soundly.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 20 (estimated)
• Ages: 21 Years and up
• Sex: All
• Sponsor: Noctrix Health, Inc. (industry)
• Locations: 1 site (Pleasanton, California)
• Trial ID: NCT06866132 on ClinicalTrials.gov

What this trial studies

This study evaluates the safety, tolerability, and effectiveness of a noninvasive neuromodulation device in patients diagnosed with restless legs syndrome (RLS). Participants will undergo a 12-week protocol that includes a 2-week baseline period without intervention, followed by 8 weeks of device usage, and concluding with a 2-week follow-up period without the device. The study aims to assess the impact of the device on RLS symptoms, particularly focusing on its ability to alleviate discomfort and improve sleep quality.

Who should consider this trial

Good fit: Ideal candidates are adults diagnosed with primary restless legs syndrome who experience moderate to severe symptoms affecting their sleep.

Not a fit: Patients with mild RLS symptoms or those who have not been diagnosed with primary restless legs syndrome may not benefit from this study.

Why it matters

Potential benefit: If successful, this device could provide a new non-pharmacological treatment option for patients suffering from restless legs syndrome.

How similar studies have performed: While this approach is relatively novel, similar studies exploring neuromodulation for other conditions have shown promising results.

Eligibility criteria

Inclusion Criteria:

1. - Subject has signed a valid, IRB-approved informed consent form, can understand the requirements of the study and instructions for device usage, and can converse in English
2. - Subject has received a medical diagnosis of primary restless legs syndrome.
3. - Subject agrees to not change dosage or schedule of any medications that are known to impact RLS symptoms during the study, including RLS medications, antidepressants, sleep medications, or sedative antihistamines.
4. - Subject has moderate-severe RLS symptoms as defined by a score of 15 or greater points on IRLS (International Restless Legs Syndrome Study Group Rating Scale) over the week prior to study entry.
5. - Subject reports that RLS symptoms caused awakenings or interfered with falling back asleep at least 3 nights per week during the month prior to study entry,
6. - Subject reports that RLS symptoms are most significant in lower legs and/or feet.

Exclusion Criteria:

1. - The subject has an active medical device implant anywhere in the body (including but not limited to pacemakers, spinal cord stimulators, deep brain stimulators).
2. - The subject has a metal implant at the site of the study device electrode application (not including knee replacements).
3. - The subject has been diagnosed with epilepsy or other seizure disorder.
4. - The subject has a moderate or severe cognitive disorder or mental illness that would affect his or her ability to participate in the study.
5. - The subject has a known allergy to device materials, electrode gel, polyurethane foam, or lycra (or a severe previous reaction to medical adhesives or bandages).
6. - Subject has any of the following at or near the location of device application: Acute injury, Cellulitis, Open sores
7. - The subject is unable or unwilling to comply with study requirements.
8. - The subject has a medical condition not listed above that may put them at risk.
9. - Subject has prior experience with any neurostimulation devices developed by the study sponsor
10. - Subject has a primary sleep disorder other than RLS that significantly interferes with sleep at the present time (e.g. obstructive sleep apnea stably controlled via CPAP would not be an exclusion).
11. - On nights with no RLS symptoms (if any), subject reports typical sleep onset latency of \>60min.
12. - Subject has severe peripheral neuropathy affecting the lower legs and/or subject has neuropathy and is unable to clearly distinguish between symptoms of neuropathy and symptoms of RLS.
13. - Subject reports that bedtime is typically outside of 9pm-3am or reports that bedtime regularly varies by more than 4 hours, such as due to shift work.
14. - During initial device set-up, device does not properly fit the subject or calibrated intensity settings are outside of operational range

Where this trial is running

Pleasanton, California

• Noctrix Health Headquarters — Pleasanton, California, United States (RECRUITING)

Study contacts

• Study coordinator: Jonathan D Charlesworth, PhD

Conditions: Restless Legs Syndrome